Molecular mechanisms of genetic polymorphisms of drug metabolism

被引:388
|
作者
Meyer, UA [1 ]
Zanger, UM [1 ]
机构
[1] DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL,D-70376 STUTTGART,GERMANY
关键词
genetic polymorphism; CYP2D6; CYP2C19; N-acetyltransferases; drug metabolism; pharmacogenetics;
D O I
10.1146/annurev.pharmtox.37.1.269
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One of the major causes of interindividual variation of drug effects is generic variation of drug metabolism. Genetic polymorphisms of drug-metabolizing enzymes give rise to distinct subgroups in the population that differ in their ability to perform certain drug biotransformation reactions. Polymorphisms are generated by mutations in the genes for these enzymes, which cause decreased, increased, or absent enzyme expression or activity by multiple molecular mechanisms. Moreover, the variant alleles exist in the population at relatively high frequency. Genetic polymorphisms have been described for most drug metabolizing enzymes. The molecular mechanisms of three polymorphisms are reviewed here. The acetylation polymorphism concerns the metabolism of a variety of arylamine and hydrazine drugs, as well as carcinogens by the cytosolic N-acetyltransferase NAT2. Seven mutations of the NAT2 gene that occur singly or in combination define numerous alleles associated with decreased function. The debrisoquine-sparteine polymorphism of drug oxidation affects the metabolism of more than 40 drugs. The poor metabolizer phenotype is caused by several ''loss of function'' alleles of the cytochrome P450 CYP2D6 gene. On the other hand, ''ultrarapid'' metabolizers are caused by duplication or amplification of an active CYP2D6 gene. Intermediate metabolizers are often heterozygotes or carry alleles with mutations that decrease enzyme activity only moderately. The mephenytoin polymorphism affects the metabolism of mephenytoin and several other drugs. Two mutant alleles of CYP2C19 have so far been identified to cause this polymorphism. These polymorphisms show recessive transmission of the poor or slow metabolizer phenotype, i.e. two mutant alleles define the genotype in these individuals. Simple DNA tests based on the primary mutations have been developed to predict the phenotype. Analysis of allele frequencies in different populations revealed major differences, thereby tracing the molecular history and evolution of these polymorphisms.
引用
收藏
页码:269 / 296
页数:28
相关论文
共 50 条
  • [2] GENETIC POLYMORPHISMS OF DRUG-METABOLIZING-ENZYMES - MOLECULAR MECHANISMS
    MEYER, UA
    ACTA PHARMACEUTICA JUGOSLAVICA, 1990, 40 (03): : 491 - 499
  • [3] GENETIC POLYMORPHISMS OF DRUG-METABOLISM
    MEYER, UA
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 (06) : 595 - 615
  • [4] GENETIC POLYMORPHISMS IN DRUG-METABOLISM
    ALVAN, G
    JOURNAL OF INTERNAL MEDICINE, 1992, 231 (06) : 571 - 573
  • [5] Molecular clock mechanisms of drug metabolism
    Shigehiro, Ohdo
    Naoya, Matsunaga
    Satoru, Koyanagi
    16TH INTERNATIONAL CONFERENCE ON CYTOCHROME P450, PROCEEDINGS, 2009, : 149 - 154
  • [6] MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS RELATED TO OCCUPATIONAL DISEASES
    Oztan, Gozde
    Issever, Halim
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2020, 83 (02): : 152 - 161
  • [7] Molecular mechanisms of drug metabolism in the critically ill
    Park, GR
    BRITISH JOURNAL OF ANAESTHESIA, 1996, 77 (01) : 32 - 49
  • [8] Polymorphisms in drug metabolism
    Rockett J.C.
    Genome Biology, 2 (12)
  • [9] Stereoselectivity in Drug Metabolism: Molecular Mechanisms and Analytical Methods
    Campo, Vanessa L.
    Bernardes, Lilian S. C.
    Carvalho, Ivone
    CURRENT DRUG METABOLISM, 2009, 10 (02) : 188 - 205
  • [10] Molecular mechanisms and drug therapy of metabolism disorders in psoriasis
    Liang, Yanyang
    Wang, Ying
    Peng, Aihong
    Li, Junqin
    Zhang, Kaiming
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)